AbbVie Corporation (April 9, 2018). Product Monograph Synagis® (palivizumab) solution for injection 50 mg/0.5ml and 100 mg/ml Intramuscular Injections.
Committee on Infectious Diseases American Academy of Pediatrics. Red Book: 2018-2021 Report of the Committee on Infectious Diseases. Itasca, IL; 2018. URL (528 https://online.statref.com/Document.aspx?FxId=76&SessionID=2A3953ELWGUKXWRS#H&1&ChaptersTab&UHOsAWxnX1ooAz3HP2xxIw!!&&76). Accessed October 02, 2018.
Canadian Communicable Disease Report, Statement of the recommended use of monoclonal anti-RSV antibody, 15 September 2003, Volume 29, ACS-7,8.
Position statement: Preventing hospitalizations for respiratory syncytial virus infection. Robinson Joan L, Le Saux Nicole; Canadian Paediatric Society, Infectious Diseases and Immunization Committee. Paediatr Child Health 2015; 20(6):321-26
Canadian Pediatric Society Position Statement. Use of palivizumab in children with congenital heart disease. Paediatrics & Child Health 2009; Vol 14 No 8.
Feltes TF, Cabalka AK, Meissner HC et al. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143:532-40.
Ryan VR, Langley JM, Dodds L, Andreou P. Estimating Respiratory Syncytial Virus –associated hospitalization in the first year of life among infants born at 32 – 35 weeks gestation. Pediatr Infect Dis J 2016;35:851-855 doi: 10.1097/INF.0000000000001186